Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P42658
UPID:
DPP6_HUMAN
Alternative names:
DPPX; Dipeptidyl aminopeptidase-related protein; Dipeptidyl peptidase 6; Dipeptidyl peptidase IV-like protein; Dipeptidyl peptidase VI
Alternative UPACC:
P42658
Background:
Dipeptidyl aminopeptidase-like protein 6 (DPP6) plays a crucial role in modulating the activity and gating characteristics of the potassium channel KCND2. It promotes cell surface expression of KCND2, influencing cardiac and neurological functions. Despite lacking dipeptidyl aminopeptidase activity, DPP6's involvement in potassium channel modulation underscores its significance in cellular physiology.
Therapeutic significance:
DPP6 is implicated in familial paroxysmal ventricular fibrillation 2, a cardiac arrhythmia, and intellectual developmental disorder, autosomal dominant 33, characterized by microcephaly and intellectual disability. These associations highlight DPP6 as a potential target for therapeutic intervention in cardiac and neurological disorders.